FI117136B - Förfarande för framställning av terapeutiskt användbara analoger av erytropoietin - Google Patents
Förfarande för framställning av terapeutiskt användbara analoger av erytropoietin Download PDFInfo
- Publication number
- FI117136B FI117136B FI951792A FI951792A FI117136B FI 117136 B FI117136 B FI 117136B FI 951792 A FI951792 A FI 951792A FI 951792 A FI951792 A FI 951792A FI 117136 B FI117136 B FI 117136B
- Authority
- FI
- Finland
- Prior art keywords
- epo
- erythropoietin
- analog
- pro
- human
- Prior art date
Links
- 0 CC(CCC=*)C1CC(C2)CC=C(C)C2CCCC2C=C(C)C2C(CC*)CCCC1 Chemical compound CC(CCC=*)C1CC(C2)CC=C(C)C2CCCC2C=C(C)C2C(CC*)CCCC1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Förfarande for framställning av en terä] användbar analog av humant erytropoietin, varvid 5 (a) nämnda analog innehäller ätminstone e1 satt N-glykosylationsställe i en asparaginrest at] vid en av aminosyrapositionerna 30, 51, 57, 88, och 138 och atminstone en tillsatt N-kopplad kolhy ja har bundits till vilken som heist av nämnda am 10 positioner, eller (b) nämnda analog innehäller en förlängnir eller flera aminosyror i karboxylterminalen av ery tin, vilken förlängning innehäller ätminstone ett < lationsställe, eller 15 (c) nämnda analog omfattar avlagsning av e- flera glykosylationsställen för humant erytropoie en lika stor tillsats av icke-naturliga glykosyl. tallen, varvid kolhydratkedjornas positioner ändra; (d) nämnda analog innehäller ett extra < 20 sylationsställe vid aminosyrapositionen 123 och € O-kopplad kolhydratkedja har bundits tili nämnda < ,·. : raposition, • ·« kännetecknad av odling av en däggdji • ♦ · som omfattar en DNA-sekvens som kodar för nämndc • · • a • . 25 för humant erytropoietin, och den sälunda erhälln< gen isoleras. • · · *·· · 2. Förfarande enligt patentkrav 1, kannet • · · : av att analogen för humant erytropoietin är: Asn30Thr32Val87Asn88Thr90EPO. 30 3. Förfarande enligt patentkrav 1, kannet !**’: av att analoaen för humant ervtroDoietin väli s bl; Ser87Asn88Thr90 EPO; Ser87Asn88Gly89Thr90 EPO; SerB7AsnseThr90Thr92 EPO; Ser87Asn88Thr90Ala162 EPO;
5 Asn69Thr71Ser87Asn88Thr90 EPO; Asn89Ile90Thr91 EPO; Ser87Asn89Ile90Thr91 EPO; Asn135Thr138 EPO; och Asn138Thr140 EPO. 10 4. Förfarande enligt patentkrav 1, kännet av att förlängningen omfattar ett peptidfragment letts frän karboxiterminalen för humant koriongc pin.
5. Förfarande enligt patentkrav 4, kännet 15 av att analogen väljs bland följande: (a) humant erytropoietin med aminosyras Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Se Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pr som tillägg tili karboxiterminalen; 20 (b) analogen enligt punkt (a) vilken dess fattar Ser87Asn88Thr90 EPO; och : (c) analogen enligt punkt (a) vilken dess .·:·[ fattar Asn30Thr32Val87Asn88Thr90 EPO. « «
6. Förfarande enligt patentkrav 1, kännet * 4* * . 25 av att det icke-naturliga glykosylationsstället ä kopplat kolhydratställe vid aminosyrapositionen 88 4 * * * mant erytropoietin. : 7. Förfarande enligt patentkrav 6, kännet av att analogen väljs bland följande: : 30 Gln24Ser87Asn88Thr90 EPO; ***** n38Qar07aQnS8Thr9() TT DA * 85 1 1
9. DNA-sekvens, kännetecknad av att d för en analog för humant erytropoietin enligt nägo tentkraven 1-8.
10. Eukaryotisk värdcell, kännetecknad 5 den transfekterats med en DNA-sekvens enligt pate pä ett sätt som tillater att värdcellen uttrycker log.
11. Värdcell enligt patentkrav 10, kännet av att den är en CHO-cell. .\ : • ·· • · < I « • · ♦ ♦ * · • M * • · • * ♦ · · • * « · : ♦ ♦ ·.· * • « « • « · ··· ♦ · * ·
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10801693A | 1993-08-17 | 1993-08-17 | |
US10801693 | 1993-08-17 | ||
PCT/US1994/009257 WO1995005465A1 (en) | 1993-08-17 | 1994-08-16 | Erythropoietin analogs |
US9409257 | 1994-08-16 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI951792A0 FI951792A0 (sv) | 1995-04-13 |
FI951792A FI951792A (sv) | 1995-05-18 |
FI117136B true FI117136B (sv) | 2006-06-30 |
Family
ID=22319789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI951792A FI117136B (sv) | 1993-08-17 | 1995-04-13 | Förfarande för framställning av terapeutiskt användbara analoger av erytropoietin |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP0640619B2 (sv) |
JP (3) | JP2938572B2 (sv) |
KR (2) | KR100328769B1 (sv) |
CN (1) | CN1057534C (sv) |
AT (1) | ATE155796T1 (sv) |
AU (1) | AU677097B2 (sv) |
CA (1) | CA2147124C (sv) |
CZ (3) | CZ291229B6 (sv) |
DE (2) | DE10199059I2 (sv) |
DK (1) | DK0640619T4 (sv) |
ES (1) | ES2105442T5 (sv) |
FI (1) | FI117136B (sv) |
GR (1) | GR3024815T3 (sv) |
HK (1) | HK1001589A1 (sv) |
HU (1) | HU220334B (sv) |
IL (4) | IL192290A0 (sv) |
LU (1) | LU90850I2 (sv) |
LV (1) | LV10972B (sv) |
NL (1) | NL300075I2 (sv) |
NO (2) | NO323104B1 (sv) |
NZ (1) | NZ273134A (sv) |
RU (1) | RU2159814C2 (sv) |
SI (1) | SI0640619T2 (sv) |
SK (1) | SK282003B6 (sv) |
UA (1) | UA49793C2 (sv) |
WO (1) | WO1995005465A1 (sv) |
ZA (1) | ZA946122B (sv) |
Families Citing this family (234)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5989538A (en) * | 1995-02-15 | 1999-11-23 | Amgen Inc. | Mpl ligand analogs |
US5696250A (en) * | 1995-02-15 | 1997-12-09 | Amgen Inc. | DNA encoding megakaryocyte growth and development factor analogs |
WO1997013783A1 (en) * | 1995-10-09 | 1997-04-17 | Pharmacia & Upjohn Company | An acceptor polypeptide for an n-acetylgalactosaminyltransferase |
KR100400637B1 (ko) * | 1996-02-06 | 2004-03-10 | 씨제이 주식회사 | 생물학적으로유용한펩타이드 |
IL125839A0 (en) | 1996-03-14 | 1999-04-11 | Genentech Inc | Uses of gdnf and gdnf receptor |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
PT902085E (pt) * | 1997-09-01 | 2004-02-27 | Aventis Pharma Gmbh | Eritropoietina humana recombinante com perfil de glicosilacao vantajoso |
CA2312188C (en) | 1997-12-08 | 2010-06-29 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
DK1088084T3 (da) | 1998-06-15 | 2007-01-29 | Gtc Biotherapeutics Inc | Erythropoietin analog-humant serumalbumin fusionsprotein |
US7304150B1 (en) | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
DK1123313T3 (da) * | 1998-10-23 | 2007-06-18 | Amgen Inc | Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
WO2000047741A1 (en) * | 1999-02-12 | 2000-08-17 | Amgen Inc. | Glycosylated leptin compositions and related methods |
US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US6555343B1 (en) | 1999-05-07 | 2003-04-29 | Genentech Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
MXPA01011264A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Nuevos polipeptidos de eritropoyetina de chimpance (chepo) y aciodos nucleicos que codifican los mismos. |
US6831060B2 (en) | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
EP1228214A2 (en) * | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
EP1961425B1 (en) * | 2000-04-21 | 2017-07-19 | Amgen Inc. | Methods and erythropoeitin analogs for the prevention and treatment of anemia |
CN1309416C (zh) | 2000-05-15 | 2007-04-11 | 霍夫曼-拉罗奇有限公司 | 新的药物组合物 |
US7259146B2 (en) | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
EP2311492B1 (en) | 2000-08-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilized preparations |
KR101229995B1 (ko) | 2000-12-11 | 2013-02-06 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
ATE320449T1 (de) * | 2000-12-11 | 2006-04-15 | Cheil Jedang Corp | Fusionsprotein mit verbesserter in vivo erythropoietinwirkung |
BR0116381A (pt) | 2000-12-20 | 2004-02-25 | Hoffmann La Roche | Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
DK1471871T3 (da) | 2001-02-02 | 2007-09-17 | Ortho Mcneil Pharm Inc | Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin |
KR100900176B1 (ko) | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
ES2869895T3 (es) | 2001-03-09 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Método de purificación de proteínas |
DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
EP1382964A4 (en) | 2001-04-17 | 2009-06-10 | Chugai Pharmaceutical Co Ltd | METHOD FOR TENSID QUANTIFICATION |
CA2446087C (en) | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
MXPA04005068A (es) | 2001-11-28 | 2004-08-19 | Ortho Mcneil Pharm Inc | Regimen de dosis de eritropoyetina para el tratamiento de la anemia. |
KR100467750B1 (ko) * | 2001-11-29 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
KR100467751B1 (ko) | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
AU2002357784B2 (en) | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
EP1465987B1 (en) | 2001-12-07 | 2008-01-23 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
DK1463751T3 (da) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
DE10209822A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
US7129267B2 (en) | 2002-03-11 | 2006-10-31 | Janssen Pharmaceutica N.V. | Methods for SHP1 mediated neuroprotection |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
CA2491567A1 (en) * | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
AU2003246486A1 (en) * | 2002-07-19 | 2004-02-09 | Cangene Corporation | Pegylated erythropoietic compounds |
DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
WO2004019966A1 (ja) | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
AU2003263552A1 (en) * | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
DE20321793U1 (de) | 2002-09-11 | 2010-06-02 | Fresenius Kabi Deutschland Gmbh | Hydroxyalkylstärke-Derivate |
EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
EP2261230B1 (en) | 2002-09-11 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
JP2006516534A (ja) | 2002-09-11 | 2006-07-06 | フレセニウス・カビ・ドイッチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Has化ポリペプチド、特にhas化エリスロポエチン |
AU2003273413A1 (en) | 2002-10-08 | 2004-05-04 | Fresenius Kabi Deutschland Gmbh | Pharmaceutically active oligosaccharide conjugates |
CA2502539A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
JP4494977B2 (ja) | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質 |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
CN101328473B (zh) | 2003-05-09 | 2012-05-02 | 克鲁塞尔荷兰公司 | E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法 |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
EA010650B1 (ru) | 2003-09-29 | 2008-10-30 | Уоррен Фармасьютикалз, Инк. | Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
ATE469654T1 (de) | 2003-12-30 | 2010-06-15 | Augustinus Bader | Verwendung des erythropoietins zur regeneration von lebergewebe |
DE102004004509B4 (de) | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
EP2336192A1 (en) | 2004-03-11 | 2011-06-22 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
CN100432107C (zh) * | 2005-10-25 | 2008-11-12 | 北京大学 | 具有促红细胞生长因子活性的蛋白质及其用途 |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
EP3026109B1 (en) | 2005-12-08 | 2022-03-09 | Amgen Inc. | Improved production of glycoproteins using manganese |
US7888101B2 (en) | 2005-12-08 | 2011-02-15 | Amgen Inc. | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
EP1997505A4 (en) | 2006-03-22 | 2013-02-13 | Chugai Pharmaceutical Co Ltd | PREPARATION OF ERYTHROPOIETIN SOLUTION |
CN101062407A (zh) | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | 促红细胞生成素在预防或治疗视网膜损伤中的用途 |
MX2008014744A (es) | 2006-05-19 | 2009-02-10 | Glycofi Inc | Composiciones de eritrocpoyetina. |
AU2007275638B2 (en) | 2006-07-21 | 2014-01-16 | Amgen Inc. | Method of detecting and/ or measuring hepcidin in a sample |
US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
CA2661054A1 (en) | 2006-08-22 | 2008-02-28 | Chugai Seiyaku Kabushiki Kaisha | Prophylactic and/or therapeutic agents for peripheral neuropathy |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
CN101337988B (zh) * | 2006-10-31 | 2013-01-09 | 沈阳三生制药有限责任公司 | 一种新的促红细胞生成素类似物 |
US8895303B2 (en) | 2006-11-13 | 2014-11-25 | Charite-Universitatsmedizin Berlin | Method of cell culture and method of treatment comprising a vEPO protein variant |
CN101678079B (zh) | 2006-11-28 | 2013-12-25 | 韩诺生物制约株式会社 | 修饰的促红细胞生成素多肽及其治疗用途 |
AR065613A1 (es) | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
WO2008124406A2 (en) | 2007-04-03 | 2008-10-16 | Neose Technologies, Inc. | Methods of treatment using glycopegylated g-csf |
EP2170919B8 (en) | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Improved process for the production of nucleotide sugars |
AU2008261212A1 (en) * | 2007-06-15 | 2008-12-18 | University Of Zurich | Treatment for Alzheimer' s disease |
CN103073631A (zh) * | 2007-07-02 | 2013-05-01 | 沈阳三生制药有限责任公司 | 一种促红细胞生成素类似物 |
CN103113464B (zh) * | 2007-07-02 | 2014-08-20 | 沈阳三生制药有限责任公司 | 天然人促红细胞生成素类似物 |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
WO2009064838A1 (en) | 2007-11-15 | 2009-05-22 | Amgen, Inc. | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
EP2070950A1 (en) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
EP2574628B1 (en) | 2008-01-25 | 2015-05-20 | Amgen Inc. | Ferroportin antibodies and methods of use |
NZ602170A (en) | 2008-02-08 | 2014-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
EP2095829A1 (en) | 2008-02-27 | 2009-09-02 | LEK Pharmaceuticals D.D. | Selenium containing modifying agents and conjugates |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
US20110137011A1 (en) | 2008-04-21 | 2011-06-09 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
WO2009139822A1 (en) | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
WO2010034442A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
WO2010036964A2 (en) | 2008-09-26 | 2010-04-01 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
CN102215869B (zh) | 2008-11-13 | 2015-05-13 | 通用医疗公司 | 用于通过调整bmp-6来调节铁稳态的方法和组合物 |
AU2010216475B2 (en) * | 2009-02-19 | 2015-07-09 | Xellia Pharmaceuticals Aps | Process for purifying lipopeptides |
US20100272816A1 (en) | 2009-04-27 | 2010-10-28 | Wolfgang Rudinger | Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient |
EP2456871B1 (en) | 2009-07-24 | 2016-09-07 | Dr. Reddy's Laboratories, Ltd. | Production of erythropoiesis stimulating protein using metal ions |
WO2011024025A1 (en) * | 2009-08-28 | 2011-03-03 | Avesthagen Limited | An erythropoietin analogue and a method thereof |
AU2010310457B2 (en) | 2009-10-23 | 2015-07-02 | Amgen Inc. | Vial adapter and system |
KR20180037303A (ko) | 2010-06-07 | 2018-04-11 | 암젠 인크 | 약물 전달 장치 |
US20120115637A1 (en) | 2010-06-30 | 2012-05-10 | Nike, Inc. | Golf Balls Including A Crosslinked Thermoplastic Polyurethane Cover Layer Having Improved Scuff Resistance |
US8193296B2 (en) | 2010-06-30 | 2012-06-05 | Nike, Inc. | Golf balls including crosslinked thermoplastic polyurethane |
RU2451071C1 (ru) * | 2010-12-10 | 2012-05-20 | Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) | Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к рекомбинантному эритропоэтину человека (варианты) |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
CA2833748C (en) | 2011-04-20 | 2019-07-16 | Amgen Inc. | Autoinjector apparatus |
US9089739B2 (en) | 2011-08-23 | 2015-07-28 | Nike, Inc. | Multi-core golf ball having increased initial velocity |
US8979676B2 (en) | 2011-08-23 | 2015-03-17 | Nike, Inc. | Multi-core golf ball having increased initial velocity at high swing speeds relative to low swing speeds |
PT3045189T (pt) | 2011-10-14 | 2018-07-23 | Amgen Inc | Injetor e método de montagem |
KR101443257B1 (ko) * | 2011-10-18 | 2014-09-19 | 주식회사 종근당 | 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법 |
CN102788720B (zh) * | 2012-06-05 | 2016-01-06 | 西北大学 | 一种滤膜辅助分离生物样本中糖蛋白全n-连接糖链及其鉴别方法 |
MX2015006343A (es) | 2012-11-21 | 2015-10-05 | Amgen Inc | Dispositivo de administracion de farmacos. |
CN103864913A (zh) * | 2012-12-18 | 2014-06-18 | 联亚生技开发股份有限公司 | 重组蛋白 |
JP6768501B2 (ja) | 2013-03-15 | 2020-10-14 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入機、および自動注入機システム |
ES2695166T3 (es) | 2013-03-15 | 2019-01-02 | Intrinsic Lifesciences Llc | Anticuerpos antihepcidina y usos de los mismos |
EP2968760B1 (en) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
KR102287687B1 (ko) | 2013-03-22 | 2021-08-06 | 암젠 인크 | 인젝터 및 조립 방법 |
JP7086520B2 (ja) | 2013-10-24 | 2022-06-20 | アムジエン・インコーポレーテツド | インジェクター及び組み立ての方法 |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
KR101414897B1 (ko) | 2013-11-29 | 2014-07-04 | 씨제이헬스케어 주식회사 | 다베포에틴 알파의 정제 방법 |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
WO2015171777A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
KR20230037063A (ko) | 2014-06-03 | 2023-03-15 | 암겐 인코포레이티드 | 제어 가능한 약물 전달 시스템 및 사용 방법 |
CN107074928B (zh) * | 2014-09-18 | 2021-03-12 | 奥美药业有限公司 | 新型猫促红细胞生成素受体激动剂 |
WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
WO2016061220A2 (en) | 2014-10-14 | 2016-04-21 | Amgen Inc. | Drug injection device with visual and audio indicators |
ES2898469T3 (es) | 2014-12-19 | 2022-03-07 | Amgen Inc | Dispositivo de administración de medicamentos con sensor de proximidad |
EP3233159B1 (en) | 2014-12-19 | 2020-03-04 | Amgen Inc. | Drug delivery device with live button or user interface field |
EP3556411B1 (en) | 2015-02-17 | 2021-06-30 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017154869A1 (ja) * | 2016-03-09 | 2017-09-14 | Jcrファーマ株式会社 | 変異型ヒトエリスロポエチンの製造方法 |
EP3429663B1 (en) | 2016-03-15 | 2020-07-15 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
WO2017197222A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
GB2550418A (en) | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
CA3048520A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
JP6258536B1 (ja) | 2017-03-03 | 2018-01-10 | 協和発酵キリン株式会社 | ダルベポエチン組成物の製造方法およびダルべポエチン産生細胞の培養方法 |
MX2019010544A (es) | 2017-03-06 | 2019-10-21 | Amgen Inc | Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion. |
SG11201908058UA (en) | 2017-03-07 | 2019-09-27 | Amgen Inc | Needle insertion by overpressure |
SG11201908062QA (en) | 2017-03-09 | 2019-09-27 | Amgen Inc | Insertion mechanism for drug delivery device |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
LT3600491T (lt) | 2017-03-28 | 2023-10-10 | Amgen Inc. | Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas |
EP3634988A4 (en) | 2017-06-06 | 2021-02-24 | Kindred Biosciences, Inc. | ERYTHROPOIETIN AND ANALOGUE FOR USE IN VETERINARY MEDICINE |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
US11541183B2 (en) | 2017-06-22 | 2023-01-03 | Amgen Inc. | Device activation impact/shock reduction |
CA3063921A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
JP2020527376A (ja) | 2017-07-21 | 2020-09-10 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
MA50614A (fr) | 2017-10-06 | 2020-08-12 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF |
US11826480B2 (en) | 2017-11-03 | 2023-11-28 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
AU2018364933B2 (en) | 2017-11-10 | 2024-01-25 | Amgen Inc. | Plungers for drug delivery devices |
MX2020005066A (es) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
JP7370969B2 (ja) | 2017-11-16 | 2023-10-30 | アムジエン・インコーポレーテツド | 薬物送達デバイスの扉ラッチ機構 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
MA53379A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
AR113091A1 (es) | 2018-09-27 | 2020-01-22 | Univ Nacional Del Litoral | Eritropoyetina humana modificada |
US20210228811A1 (en) | 2018-09-28 | 2021-07-29 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
CN112805048B (zh) | 2018-10-02 | 2023-09-22 | 安进公司 | 具有内部力传递的用于药物递送的注射系统 |
MA53818A (fr) | 2018-10-05 | 2022-01-12 | Amgen Inc | Dispositif d'administration de médicament ayant un indicateur de dose |
EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
CA3113076A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
WO2020219482A1 (en) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
CN117320964A (zh) | 2021-05-21 | 2023-12-29 | 美国安进公司 | 优化药物容器的灌装方案的方法 |
WO2023209074A1 (en) | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
WO2024094457A1 (en) | 2022-11-02 | 2024-05-10 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4954437A (en) * | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
AU646822B2 (en) * | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
-
1994
- 1994-08-15 IL IL192290A patent/IL192290A0/en unknown
- 1994-08-15 ZA ZA946122A patent/ZA946122B/xx unknown
- 1994-08-15 CN CN94109128A patent/CN1057534C/zh not_active Expired - Lifetime
- 1994-08-15 IL IL110669A patent/IL110669A/en not_active IP Right Cessation
- 1994-08-16 JP JP7507153A patent/JP2938572B2/ja not_active Expired - Lifetime
- 1994-08-16 DE DE2001199059 patent/DE10199059I2/de active Active
- 1994-08-16 DK DK94112732T patent/DK0640619T4/da active
- 1994-08-16 DE DE69404401T patent/DE69404401T3/de not_active Expired - Lifetime
- 1994-08-16 AU AU76327/94A patent/AU677097B2/en not_active Expired
- 1994-08-16 AT AT94112732T patent/ATE155796T1/de active
- 1994-08-16 NZ NZ273134A patent/NZ273134A/en not_active IP Right Cessation
- 1994-08-16 KR KR1019950701453A patent/KR100328769B1/ko not_active IP Right Cessation
- 1994-08-16 RU RU95115239/14A patent/RU2159814C2/ru active
- 1994-08-16 SI SI9430078T patent/SI0640619T2/xx unknown
- 1994-08-16 CZ CZ1995917A patent/CZ291229B6/cs not_active IP Right Cessation
- 1994-08-16 SK SK502-95A patent/SK282003B6/sk unknown
- 1994-08-16 UA UA95058432A patent/UA49793C2/uk unknown
- 1994-08-16 EP EP94112732A patent/EP0640619B2/en not_active Expired - Lifetime
- 1994-08-16 CA CA002147124A patent/CA2147124C/en not_active Expired - Lifetime
- 1994-08-16 WO PCT/US1994/009257 patent/WO1995005465A1/en active IP Right Grant
- 1994-08-16 ES ES94112732T patent/ES2105442T5/es not_active Expired - Lifetime
- 1994-08-16 HU HU9501435A patent/HU220334B/hu active Protection Beyond IP Right Term
-
1995
- 1995-04-12 NO NO19951445A patent/NO323104B1/no not_active IP Right Cessation
- 1995-04-13 FI FI951792A patent/FI117136B/sv not_active IP Right Cessation
- 1995-04-15 KR KR1019957001453A patent/KR960701994A/ko unknown
- 1995-04-17 LV LVP-95-99A patent/LV10972B/en unknown
-
1997
- 1997-09-22 GR GR970402449T patent/GR3024815T3/el unknown
-
1998
- 1998-01-21 HK HK98100522A patent/HK1001589A1/xx not_active IP Right Cessation
- 1998-08-24 JP JP25324498A patent/JP3664590B2/ja not_active Expired - Lifetime
-
2000
- 2000-05-16 IL IL13618800A patent/IL136188A0/xx unknown
- 2000-05-16 IL IL13618900A patent/IL136189A0/xx unknown
-
2001
- 2001-02-06 CZ CZ2001462A patent/CZ291342B6/cs not_active IP Right Cessation
- 2001-02-06 CZ CZ2001463A patent/CZ291343B6/cs not_active IP Right Cessation
- 2001-11-07 LU LU90850C patent/LU90850I2/fr unknown
- 2001-12-06 NL NL300075C patent/NL300075I2/nl unknown
-
2004
- 2004-06-25 JP JP2004188815A patent/JP3664723B2/ja not_active Expired - Lifetime
-
2007
- 2007-06-29 NO NO2007008C patent/NO2007008I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI117136B (sv) | Förfarande för framställning av terapeutiskt användbara analoger av erytropoietin | |
US7217689B1 (en) | Glycosylation analogs of erythropoietin | |
KR100221066B1 (ko) | 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물 | |
US5856298A (en) | Erythropoietin isoforms | |
CN108290937A (zh) | 长效fgf21融合蛋白及包含其的药物组合物 | |
JPH07508420A (ja) | 肝細胞成長因子変異体 | |
KR20130132880A (ko) | 간암의 치료에 사용하기 위한 robo1-fc 융합 단백질 | |
FI106563B (sv) | Förfarande för framställning av humana erytropoietinanaloger och DNA-sekvenser som kodar dessa | |
KR102668200B1 (ko) | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assigment of application |
Owner name: KIRIN-AMGEN INC. |
|
FG | Patent granted |
Ref document number: 117136 Country of ref document: FI |
|
SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20060020 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: 302 Extension date: 20160608 |
|
MA | Patent expired |